CA2124967C - Animaux transgeniques non humains capables de produire des anticorps heterologues - Google Patents

Animaux transgeniques non humains capables de produire des anticorps heterologues Download PDF

Info

Publication number
CA2124967C
CA2124967C CA002124967A CA2124967A CA2124967C CA 2124967 C CA2124967 C CA 2124967C CA 002124967 A CA002124967 A CA 002124967A CA 2124967 A CA2124967 A CA 2124967A CA 2124967 C CA2124967 C CA 2124967C
Authority
CA
Canada
Prior art keywords
human
sequences
transgene
gene
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002124967A
Other languages
English (en)
Other versions
CA2124967A1 (fr
Inventor
Nils Lonberg
Robert M. Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genpharm International Inc
Original Assignee
Genpharm International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/810,279 external-priority patent/US5569825A/en
Priority claimed from US07/853,408 external-priority patent/US5789650A/en
Application filed by Genpharm International Inc filed Critical Genpharm International Inc
Publication of CA2124967A1 publication Critical patent/CA2124967A1/fr
Application granted granted Critical
Publication of CA2124967C publication Critical patent/CA2124967C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002124967A 1991-12-17 1992-12-17 Animaux transgeniques non humains capables de produire des anticorps heterologues Expired - Lifetime CA2124967C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/810,279 US5569825A (en) 1990-08-29 1991-12-17 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US07/810,279 1991-12-17
US07/853,408 US5789650A (en) 1990-08-29 1992-03-18 Transgenic non-human animals for producing heterologous antibodies
US07/853,408 1992-03-18
US90406892A 1992-06-23 1992-06-23
US07/904,068 1992-06-23
PCT/US1992/010983 WO1993012227A1 (fr) 1991-12-17 1992-12-17 Animaux transgeniques non humains capables de produire des anticorps heterologues

Publications (2)

Publication Number Publication Date
CA2124967A1 CA2124967A1 (fr) 1993-06-24
CA2124967C true CA2124967C (fr) 2008-04-08

Family

ID=27420056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124967A Expired - Lifetime CA2124967C (fr) 1991-12-17 1992-12-17 Animaux transgeniques non humains capables de produire des anticorps heterologues

Country Status (5)

Country Link
EP (1) EP0746609A4 (fr)
JP (2) JPH07503132A (fr)
AU (1) AU3328493A (fr)
CA (1) CA2124967C (fr)
WO (1) WO1993012227A1 (fr)

Families Citing this family (763)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0754225A4 (fr) * 1993-04-26 2001-01-31 Genpharm Int Animaux transgeniques capables de produire des anticorps heterologues
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU2008202860B9 (en) * 1995-04-27 2012-03-29 Amgen Fremont Inc. Human Antibodies Derived From Immunized Xenomice
KR100654645B1 (ko) * 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU4376400A (en) * 1995-04-27 2000-11-30 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
AU2405297A (en) 1996-04-23 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
AU713473B2 (en) 1996-12-23 1999-12-02 Immunex Corporation Receptor activator of NF-kappa B, receptor is member of TNF receptor superfamily
ES2382488T3 (es) 1997-03-21 2012-06-08 Chugai Seiyaku Kabushiki Kaisha Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo
KR100496063B1 (ko) 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9711167D0 (en) * 1997-05-31 1997-07-23 Babraham The Inst Telomere-associated chromosome fragmentation
ATE395933T1 (de) 1997-08-15 2008-06-15 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
WO1999015696A1 (fr) * 1997-09-19 1999-04-01 Medelys Laboratories Inc. Procede et kit de diagnostic precoce de l'auto-immunite et du lymphome dans le systeme nerveux central
CA2251263A1 (fr) * 1997-11-14 1999-05-14 Hajime Karasuyama Modeles d'allergie d'animal transgenique et methodes d'utilisation
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DE60023451T2 (de) * 1999-02-05 2006-07-20 Therapeutic Human Polyclonals, Inc., Mountain View Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
EP1604997A1 (fr) * 1999-02-05 2005-12-14 Therapeutic Human Polyclonals, Inc. Anticorps humains polyclonaux d'animaux génétiquement modifiés
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
DE60039596D1 (de) * 1999-03-30 2008-09-04 Japan Tobacco Inc Verfahren zur herstellung von monoklonalen antikörpern
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN1370076A (zh) 1999-08-23 2002-09-18 中外制药株式会社 Hm1.24抗原的表达增强剂
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU6871900A (en) 1999-09-06 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Tsg-like gene
JP4838961B2 (ja) 1999-09-21 2011-12-14 中外製薬株式会社 トランスポーター遺伝子ｏａｔｐ−ｂ、ｃ、ｄ、およびｅ
KR20030008205A (ko) 1999-10-01 2003-01-24 추가이 세이야쿠 가부시키가이샤 혈액응고 관련 질환의 예방 및 치료
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
US20030086929A1 (en) 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP4364645B2 (ja) 2002-02-14 2009-11-18 中外製薬株式会社 抗体含有溶液製剤
DK1485477T3 (da) 2002-02-25 2009-08-10 Genentech Inc Hidtil ukendt type-1-cytokinreceptor GLM-R
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1494714A4 (fr) 2002-04-05 2008-03-05 Amgen Inc Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl
IL164287A0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
JP2005535636A (ja) 2002-06-28 2005-11-24 アメリカ合衆国 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
RU2377253C2 (ru) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
CN1767852B (zh) 2003-01-31 2010-04-14 塞尔德克斯医疗公司 抗体疫苗缀合物及其用途
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
CA2527694C (fr) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Banque de fab pour la preparation de fab anti-vegf et antirabique
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
CA2542232A1 (fr) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Methode de traitement des maladies neurodegeneratives par inhibation de l'alpha-synucleine
EP2228445A1 (fr) 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Transporteur du fucose
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CN1914320A (zh) 2003-12-03 2007-02-14 中外制药株式会社 利用哺乳类β肌动蛋白启动子的表达体系
MXPA06005941A (es) 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
CA2546054C (fr) 2003-12-10 2014-05-13 Medarex, Inc. Anticorps contre l'interferon alpha et leur utilisations
EP1710255A4 (fr) 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd Anticorps modifies reconnaissant un recepteur trimere ou plus grand
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
JP2008507257A (ja) 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Ｖ遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
EP2343384A3 (fr) 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Procédé de diagnostic du cancer pulmonaire à grandes cellules
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
KR101541658B1 (ko) 2004-06-21 2015-08-07 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
WO2006003179A2 (fr) 2004-07-01 2006-01-12 Novo Nordisk A/S Anticorps anti-kir humains
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
CN111925445A (zh) 2004-07-09 2020-11-13 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
CA2585098C (fr) 2004-10-22 2018-12-18 Revivicor, Inc. Sequences genomiques porcines kappa et lambda a chaine legere
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
PL1838733T3 (pl) 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP2208783A1 (fr) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Procédé de préparation d'un anticorps à l'aide d'une cellule dont la fonction de transporteur du fucose est inhibée
CA2590164A1 (fr) 2005-01-26 2006-08-03 Amgen Fremont Inc. Anticorps diriges contre interleukine-1 beta
WO2006104677A2 (fr) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Anticorps se liant a ov064 et leurs methodes d'utilisation
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
US20100003254A1 (en) 2005-04-08 2010-01-07 Chugai Seiyaku Kabushiki Kaisha Antibody Substituting for Function of Blood Coagulation Factor VIII
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
CA2610987C (fr) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
NO345593B1 (no) 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
NZ594784A (en) 2005-08-18 2013-06-28 Genmab As Therapy with CD4 binding peptides and radiation
EP1934867A2 (fr) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2623236A1 (fr) 2005-09-26 2007-04-05 Medarex, Inc. Anticorps monoclonaux humains diriges contre cd70
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
EP2532679B1 (fr) 2005-10-21 2017-04-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
EP2548583A3 (fr) 2005-11-10 2013-02-27 Curagen Corporation Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
EP1964574B1 (fr) 2005-11-14 2016-09-07 Cellmid Limited Procede de traitement ou de prevention d une maladie associee a un trouble fonctionnel des lymphocytes t regulateurs
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
CA2630157C (fr) 2005-12-07 2018-01-09 Medarex, Inc. Regimes d'escalade de dose d'anticorps ctla-4
PL1960434T3 (pl) 2005-12-08 2012-12-31 Squibb & Sons Llc Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
WO2007074880A1 (fr) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007084321A2 (fr) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Anticorps dirigés contre ox-2/cd200 et utilisations correspondantes
WO2007084672A2 (fr) 2006-01-17 2007-07-26 Medarex, Inc. Anticorps monoclonaux anti-cd30 dépourvus de résidus fucosyl et xylosyl
WO2009051846A2 (fr) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans l'épithélioma pulmonaire humain à grandes cellules
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2685915T3 (es) 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
EP4218801A3 (fr) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP4342995A3 (fr) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2010567A2 (fr) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Compositions d'anticorps et méthodes de traitement d'une maladie néoplasique
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
EP2025346B1 (fr) 2006-04-07 2016-08-10 Osaka University Promoteur de régénération musculaire
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007119796A1 (fr) 2006-04-14 2007-10-25 Medical And Biological Laboratories Co., Ltd. Polypeptide mutant doté d'une fonction d'effecteur
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (fr) 2007-07-27 2009-02-05 Elan Pharma International Limited Traitement de maladies amyloïdogéniques
JP5311303B2 (ja) 2006-04-25 2013-10-09 国立大学法人 東京大学 アルツハイマー病および癌の治療薬
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
MY157796A (en) 2006-06-08 2016-07-29 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
RU2009100930A (ru) 2006-06-14 2010-07-20 Чугаи Сейяку Кабусики Кайся (Jp) Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
MX2009000487A (es) 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
JP5317697B2 (ja) 2006-08-14 2013-10-16 中外製薬株式会社 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
EP2083017A4 (fr) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Anticorps présentant une activité adcc accrue et son procédé de production
AU2007320024B2 (en) 2006-10-02 2012-11-08 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
CA2665528C (fr) 2006-10-12 2018-01-23 The University Of Tokyo Diagnostic et traitement du cancer a l'aide d'un anticorps anti-ereg
EP2530090A3 (fr) 2006-10-19 2013-01-23 CSL Limited Anticorps anti-IL-13R alpha 1 et leurs utilisations
AU2007311957A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CA2666809A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancereux comprenant un anticorps anti-hb-egf en tant qu'ingredient actif
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
WO2008081942A1 (fr) 2007-01-05 2008-07-10 The University Of Tokyo Diagnostic et traitement de cancers utilisant un anticorps anti-prg-3
WO2008090901A1 (fr) 2007-01-23 2008-07-31 Shinshu University Inhibiteur de rejet chronique
JP5241518B2 (ja) 2007-02-15 2013-07-17 国立大学法人九州大学 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤
PT2129396E (pt) 2007-02-16 2013-11-18 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
CA2679266A1 (fr) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
EP1972639A3 (fr) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Réactifs pour la détection de la phosphorylation de protéines dans des voies signalant un carcinome
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
JP5721951B2 (ja) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
EP1975184A3 (fr) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Sites de phosphorylation à sérine ou thréonine
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
EP1983003A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
FI20075278A0 (fi) 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
EP2155238B1 (fr) 2007-06-05 2016-04-06 Yale University Anticorps contre le d4 domaine de récepteur kit et méthodes d'utilisation
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
JP5469456B2 (ja) 2007-06-25 2014-04-16 中外製薬株式会社 ＡＤＣＣ活性又はＣＤＣ活性を有する抗Ｐｒｏｍｉｎｉｎ−１抗体
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP2185719B1 (fr) 2007-08-02 2013-11-13 NovImmune SA Anticorps anti-rantes et leurs procédés d'utilisation
EP2185692A4 (fr) 2007-08-10 2012-05-02 Medarex Inc Hco32 et hco27 et exemples connexes
WO2009026274A1 (fr) 2007-08-22 2009-02-26 Medarex, Inc. Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
EP2615113A3 (fr) 2007-08-23 2013-11-13 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
LT2769729T (lt) 2007-09-04 2019-05-10 Compugen Ltd. Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2009041643A1 (fr) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Procédé permettant de modifier le point isoélectrique d'un anticorps par substitution d'acide aminé dans une région déterminant la complémentarité (cdr)
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
JP5264752B2 (ja) 2007-10-02 2013-08-14 中外製薬株式会社 インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CA2701338C (fr) 2007-10-15 2018-09-18 Chugai Seiyaku Kabushiki Kaisha Procede de fabrication d'anticorps
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
AU2008320823B2 (en) 2007-11-02 2013-01-17 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EA201692127A1 (ru) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
EP2918605A1 (fr) 2007-11-12 2015-09-16 U3 Pharma GmbH Anticorps axl
CN102112492B (zh) 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
RU2559530C2 (ru) 2007-11-15 2015-08-10 Чугаи Сейяку Кабусики Кайся Моноклональные антитела, способные связываться с белком axl, и их применение
EP2062920A3 (fr) 2007-11-21 2009-06-17 Peter Hornbeck Phosphorylation de protéines par des kinases de sérine/thréonine basophiles dans des voies de signalisation de l'insuline
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
WO2009075344A1 (fr) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center Agent thérapeutique pour une leucémie mll et une leucémie moz dont la cible moléculaire est le récepteur m-csf, et son utilisation
EP2769993A1 (fr) 2007-12-14 2014-08-27 Novo Nordisk A/S Anticorps contre NKG2D humain et usages correspondants
WO2009078799A1 (fr) 2007-12-17 2009-06-25 Marfl Ab Nouveau vaccin pour le traitement de troubles liés à une mycobactérie
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
SG187457A1 (en) 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
FR2926438B1 (fr) * 2008-01-22 2013-01-11 Univ Limoges Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe g et ses applications
BRPI0906387A2 (pt) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
EP2274437B1 (fr) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions et procédés pour la détection des mutations d'egfr en cas de cancer
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
MX2010012616A (es) 2008-05-29 2010-12-21 Galaxy Biotech Llc Anticuerpos monoclonales para factor de crecimiento de fibroblastos basico.
WO2009147781A1 (fr) 2008-06-02 2009-12-10 国立大学法人東京大学 Agent antitumoral
EP2305306B1 (fr) 2008-06-05 2016-02-10 National Cancer Center Inhibiteur de neuro-invasion
EP2319869B1 (fr) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTICORPS CONTRE UN COMPLEXE LDL/ß²GPT OXIDÉ ET SON UTILISATION
RU2731084C2 (ru) * 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2735900A1 (fr) 2008-09-19 2010-03-25 Medimmune, Llc Anticorps diriges contre dll4 et leurs utilisations
EP3889265A1 (fr) 2008-09-30 2021-10-06 Ablexis, LLC Souris transgeniques destinés à la production d anticorps chimériques
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010054265A2 (fr) 2008-11-07 2010-05-14 Galaxy Biotech, Llc. Anticorps monoclonaux anti-récepteur 2 du facteur de croissance des fibroblastes
WO2010054403A1 (fr) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés au complément
AU2009325878B2 (en) 2008-12-08 2014-01-16 Compugen Ltd. TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
WO2010074049A1 (fr) 2008-12-22 2010-07-01 株式会社 未来創薬研究所 Anticorps anti-hs6st2 et son utilisation
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2010073694A1 (fr) 2008-12-25 2010-07-01 国立大学法人東京大学 Diagnostic de traitement d'un cancer à l'aide d'un anticorps anti-tm4sf20
US20120014870A1 (en) 2008-12-26 2012-01-19 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
WO2010085590A1 (fr) 2009-01-23 2010-07-29 Biosynexus Incorporated Anticorps opsoniques et protecteurs spécifiques de bactéries à gram positifs à acide lipotéichoïque
ES2637174T3 (es) 2009-02-12 2017-10-11 Cell Signaling Technology, Inc. Expresión de ROS mutante en el cáncer de hígado humano
MX2011009220A (es) 2009-03-05 2011-09-28 Medarex Inc Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA2762187C (fr) 2009-04-08 2017-08-01 Olle Hernell Nouvelles methodes de traitement de maladies inflammatoires
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
BRPI1016055A2 (pt) 2009-04-27 2016-05-10 Novartis Ag composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
CA2758290C (fr) 2009-04-27 2018-04-10 Novartis Ag Anticorps anti-recepteur de l'activine iib (actriib) destines a augmenter la croissance musculaire
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
PE20121540A1 (es) 2009-05-04 2012-12-22 Abbott Res Bv Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada
MX348013B (es) 2009-05-05 2017-05-23 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos.
EP2436397B1 (fr) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant un antagoniste d'un ligand de la famille de l'egf en tant que composant
EP2445925A1 (fr) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Purification de protéines par précipitation de l'acide caprylique (l'acide octanoïque)
JP5944312B2 (ja) 2009-07-08 2016-07-05 カイマブ・リミテッド 動物モデルおよび治療用分子
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102625848A (zh) 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
SG177689A1 (en) 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla
MY161541A (en) 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
WO2011017294A1 (fr) 2009-08-07 2011-02-10 Schering Corporation Anticorps anti-rankl humain
EP2468771A4 (fr) 2009-08-17 2013-06-05 Forerunner Pharma Res Co Ltd Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif
WO2011021146A1 (fr) 2009-08-20 2011-02-24 Pfizer Inc. Anticorps contre l'ostéopontine
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
CA2777691C (fr) 2009-10-16 2018-02-27 Biorealites Anticorps monoclonaux contre la progastrine et leurs utilisations
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
WO2011057188A1 (fr) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Anticorps anti-cd20 canins
NZ599813A (en) 2009-11-09 2014-07-25 Alexion Pharma Inc Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
NO2719708T3 (fr) 2009-11-13 2018-03-24
PL2501822T3 (pl) 2009-11-17 2017-12-29 E. R. Squibb & Sons, L.L.C. Sposoby zwiększenia produkcji białek
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
RU2012134369A (ru) 2010-01-11 2014-02-20 Алексион Фармасьютикалз, Инк Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
US8685524B2 (en) 2010-01-29 2014-04-01 Toray Industries, Inc. Polylactic acid-based resin sheet
SI2530091T1 (en) 2010-01-29 2018-06-29 Chugai Seiyaku Kabushiki Kaisha PROTITELO ANTI-DLL3
WO2011097511A1 (fr) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Lymphocytes b régulateurs (tbreg) et leur utilisation
CA2789310C (fr) 2010-02-10 2018-01-09 Fujifilm Ri Pharma Co., Ltd. Anticorps anti-cadherine marque par un metal radioactif
CN105315370A (zh) 2010-02-18 2016-02-10 加利福尼亚大学董事会 整合素αVβ8中和抗体
JPWO2011105573A1 (ja) 2010-02-26 2013-06-20 株式会社 未来創薬研究所 抗ｉｃａｍ３抗体およびその用途
EP2544688B1 (fr) 2010-03-02 2016-09-07 President and Fellows of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2552947A4 (fr) 2010-03-26 2013-11-13 Dartmouth College Vista, une protéine médiatrice régulatrice des lymphocytes t, agents de liaison à vista et utilisation associée
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
KR102117771B1 (ko) 2010-03-31 2020-06-02 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2011140151A1 (fr) 2010-05-04 2011-11-10 Dyax Corp. Anticorps contre le récepteur du facteur de croissance épidermique (egfr)
CA2798273A1 (fr) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Anticorps contre le recepteur du facteur de croissance epidermique (egfr) et leurs utilisations
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
CA2798432A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6)
EP2578233B1 (fr) 2010-05-28 2017-04-26 National Cancer Center Agent thérapeutique contre le cancer du pancréas
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
WO2011154453A1 (fr) 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
EP3281956A3 (fr) 2010-06-15 2018-04-18 Genmab A/S Conjugués anticorps humain-médicament contre le facteur tissulaire
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
EP3327035A1 (fr) 2010-06-22 2018-05-30 Precision Biologics Inc. Antigènes et anticorps spécifiques des cancers du côlon et du pancréas
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
BR112013000796B1 (pt) 2010-07-14 2021-08-31 Merck Sharp & Dohme Corp Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide
ES2741175T3 (es) 2010-07-16 2020-02-10 Bioatla Llc Nuevos métodos de evolución de proteínas
EP2601220A2 (fr) 2010-08-06 2013-06-12 U3 Pharma GmbH Utilisation d'agents de liaison her3 dans le traitement de la prostate
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2606130B1 (fr) 2010-08-16 2019-03-13 Duke University Camkk-bêta en tant que marqueur du cancer de la prostate
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
WO2012035518A1 (fr) 2010-09-17 2012-03-22 Compugen Ltd. Compositions et procédés de traitement d'un myélome multiple résistant aux médicaments
TW201213342A (en) 2010-09-17 2012-04-01 Baxter Int Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH
EP2434285A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Diagnostic du cancer du sein
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
CA3182320A1 (fr) 2010-09-23 2012-03-29 Precision Biologics, Inc. Peptidomimetiques du cancer du colon et du pancreas
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
US9364505B2 (en) 2010-10-25 2016-06-14 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
ES2931477T3 (es) 2010-10-29 2022-12-29 Perseus Proteomics Inc Anticuerpo anti-CDH3 que tiene alta capacidad de internalización
PT2644698T (pt) 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
EP4231014A3 (fr) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
HUE031726T2 (en) 2010-12-06 2017-07-28 Seattle Genetics Inc Humanized antibodies and anti-cancer antibodies against LIV-1 antibodies
EP2659270A4 (fr) 2010-12-31 2014-05-21 Bioatla Llc Génération d'anticorps monoclonaux entiers
EP2668207A4 (fr) 2011-01-24 2015-06-10 Univ Singapore Protéines de liaison à l'antigène lipoarabinomannane coiffé d'un mannose provenant de mycobactéries pathogènes
CA2826453A1 (fr) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Utilisation d'un anticorps anti-cd200 pour prolonger la survie d'allogreffes
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
EP2500073A1 (fr) 2011-03-17 2012-09-19 ChromaCon AG Procédé pour l'identification et la purification de polypeptides plurispécifiques
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
WO2012142164A1 (fr) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii
BR112013026199A2 (pt) 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
EP2700652B1 (fr) 2011-04-18 2018-12-19 The University of Tokyo Diagnostic et traitement du cancer à l'aide d'un anticorps anti-itm2a
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
CA2837184C (fr) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anticorps anti-kir destines au traitement de troubles inflammatoires
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (fr) 2011-06-14 2012-12-20 Novartis Ag Compositions et procédés de ciblage du tem8 par des anticorps
US9260519B2 (en) 2011-06-17 2016-02-16 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CA2839539C (fr) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Polypeptide heterodimerise
EP2726503B1 (fr) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
EP2731970B1 (fr) 2011-07-15 2018-11-28 MorphoSys AG Anticorps à réaction croisée pour le facteur d'inhibition de la migration des macrophages et la d-dopachrome tautomérase
EP2734546A1 (fr) 2011-07-18 2014-05-28 Amgen Inc. Protéines de liaison à antigène de l'apéline et leurs utilisations
EP2735315B1 (fr) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Préparation à teneur en protéines stable renfermant de l'argininamide ou de la valinamide
WO2013017656A1 (fr) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonistes de ribonucléases pour traiter l'obésité
EP2739652B1 (fr) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Inhibiteurs cahgt1p à utiliser dans le traitement de la candidose
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
WO2013035824A1 (fr) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド Séparation de cellules souches cancéreuses
EP4091442A1 (fr) * 2011-09-19 2022-11-23 Kymab Limited Manipulation de la diversité de gènes d'immunoglobuline et multi-anticorps thérapeutiques
WO2013045916A1 (fr) 2011-09-26 2013-04-04 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
CN113061993A (zh) 2011-09-30 2021-07-02 中外制药株式会社 离子浓度依赖性结合分子文库
TW201726745A (zh) 2011-09-30 2017-08-01 中外製藥股份有限公司 促進抗原消失的抗原結合分子
WO2013047729A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule de liaison d'un antigène induisant une réponse immunitaire pour cibler l'antigène
EP2762493B1 (fr) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3617313A1 (fr) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à des antigènes pour la promotion de la clairance à partir du plasma de l'antigène comprenant un domaine récepteur-fixateur de la chaîne saccharidique
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
EP2766044B1 (fr) 2011-10-13 2019-12-11 Aerpio Therapeutics, Inc. Traitement de maladies oculaires
CN104080471B (zh) 2011-10-14 2018-08-10 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
EP2772268B8 (fr) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Molécule spécifique des cellules souches cancéreuses
WO2013063481A1 (fr) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarqueurs de réponse à des inhibiteurs de nae
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
CA2855368A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite vis-a-vis d'inhibiteurs du proteasome
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
CN118105479A (zh) 2011-11-16 2024-05-31 艾德里诺医药公司 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架
PT2594587E (pt) 2011-11-16 2014-08-27 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para diminuir o risco de mortalidade num paciente com uma doença aguda ou crónica ou num estado agudo
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
AU2012338731B2 (en) 2011-11-16 2017-07-06 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
US9535060B2 (en) 2011-11-16 2017-01-03 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
CA2856142A1 (fr) 2011-11-16 2013-05-23 Adrenomed Ag Anticorps anti-adrenomedulline (adm) ou fragment d'anticorps anti-adm ou echafaudage non-ig anti-adm pour l'application therapeutique en cas d'une maladie aigue ou d'un etat aigu d'un patient pour la stabilisation de la circulation
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013084148A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
KR102038974B1 (ko) * 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104185681A (zh) 2012-02-01 2014-12-03 卡姆普根有限公司 C1orf32抗体及其用于治疗癌症的用途
NZ628314A (en) 2012-02-06 2017-01-27 Inhibrx Lp Cd47 antibodies and methods of use thereof
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
MX370668B (es) 2012-02-24 2019-12-19 Chugai Pharmaceutical Co Ltd Molécula de unión al antígeno para promover la pérdida de antígeno a través de fc gamma riib.
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013147153A1 (fr) 2012-03-29 2013-10-03 株式会社未来創薬研究所 Anticorps anti-lamp5 et son utilisation
KR20150003251A (ko) 2012-04-04 2015-01-08 가부시키가이샤 페르세우스 프로테오믹스 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
KR102382304B1 (ko) 2012-04-20 2022-04-04 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013170168A1 (fr) 2012-05-10 2013-11-14 Bioatla Llc Anticorps monoclonaux multi-spécifiques
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP2857419B1 (fr) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison d'antigène supprimant un antigène associé
WO2013180200A1 (fr) 2012-05-30 2013-12-05 中外製薬株式会社 Molécule de liaison d'antigène spécifique à un tissu cible
CN104540961A (zh) 2012-06-11 2015-04-22 安姆根公司 双重受体拮抗性抗原结合蛋白及其用途
EP2862875B1 (fr) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha MOLÉCULE DE LIAISON À L'ANTIGÈNE CONTENANT UNE RÉGION Fc MODIFIÉE
CA2877533C (fr) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Nouveaux produits de recombinaison vista-ig et leur utilisation dans le traitement des troubles autoimmuns, allergiques et inflammatoires
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2869897A4 (fr) 2012-07-06 2016-09-28 Univ Duke Activation du canal ionique trpv4 par stimuli physiques et rôle critique de trpv4 dans l'inflammation et la démangeaison spécifique à un organe
WO2014007402A1 (fr) 2012-07-06 2014-01-09 京都府公立大学法人 Marqueur de différenciation et régulation de différenciation de cellules oculaires
FI4019041T3 (fi) 2012-07-13 2023-04-03 Univ Pennsylvania Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
NZ705370A (en) 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP2892558B1 (fr) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Modulateurs vista de diagnostic et de traitement de cancer
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
TWI606066B (zh) 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
EP2902787B1 (fr) 2012-09-28 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Procédé d'évaluation de réaction de coagulation du sang
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
PL2918603T3 (pl) 2012-11-08 2019-01-31 University Of Miyazaki Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny
CA2886987C (fr) 2012-11-08 2022-07-12 Eleven Biotherapeutics, Inc. Antagonistes de l'il-6 et leurs utilisations
WO2014084859A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Molécules et procédés pour la modulation d'activités de tmem16a
JP6306605B2 (ja) 2012-12-05 2018-04-04 ノバルティス アーゲー Ｅｐｏを標的とする抗体のための組成物および方法
EP2935589A1 (fr) 2012-12-18 2015-10-28 Novartis AG Compositions et procédés qui utilisent une étiquette peptidique qui se lie au hyaluronane
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2013370171B2 (en) 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
EA031537B1 (ru) 2013-02-08 2019-01-31 Новартис Аг Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений
EP3594231A1 (fr) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Anticorps anti-tnf-alpha hautement galactosylatés et leurs utilisations
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
WO2014165271A2 (fr) 2013-03-13 2014-10-09 Neotope Biosciences Limited Immunothérapie contre tau
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
SI2970449T1 (sl) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
WO2014140368A1 (fr) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Constructions d'anticorps pour m2 et cd3 de grippe
US9816088B2 (en) 2013-03-15 2017-11-14 Abvitro Llc Single cell bar-coding for antibody discovery
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
RU2673455C2 (ru) 2013-03-20 2018-11-27 Сфинготек Гмбх Адреномедуллин для направленной терапии по снижению кровяного давления
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2014185550A1 (fr) 2013-05-16 2014-11-20 Kyoto University Procédé de détermination d'un pronostic de cancer
CA2922704A1 (fr) 2013-05-24 2014-11-27 Neil R. Cashman Marqueurs de senescence cellulaire en tant que cibles diagnostiques et therapeutiques
WO2014200018A1 (fr) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
JPWO2014208482A1 (ja) 2013-06-24 2017-02-23 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
CA2916259C (fr) 2013-06-28 2024-02-20 Amgen Inc. Procedes de traitement d'une hypercholesterolemie familiale homozygote
EP3016683B1 (fr) 2013-07-05 2020-06-24 University of Washington through its Center for Commercialization Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2015023851A1 (fr) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
EP3041513B1 (fr) 2013-09-08 2020-08-05 Kodiak Sciences Inc. Conjugués polymère zwittérionique-facteur viii
EP3047857A4 (fr) 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Traitement de maladies hémorragiques par anticorps anti-protéine-c
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
JP7133902B2 (ja) 2013-10-01 2022-09-09 カイマブ・リミテッド 動物モデル及び治療用分子
EA201600354A1 (ru) 2013-11-11 2016-12-30 Чугаи Сеияку Кабушики Каиша Антигенсвязывающая молекула, содержащая вариабельную область антитела
TW202043467A (zh) 2013-12-04 2020-12-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
ES2920677T3 (es) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-VISTA
CA2935143C (fr) 2013-12-27 2024-05-07 Chugai Seiyaku Kabushiki Kaisha Procede de purification d'anticorps a faible point isoelectrique
WO2015099127A1 (fr) 2013-12-27 2015-07-02 中外製薬株式会社 Gène mutant de fgfr gardien et médicament ciblant celui-ci
CA2935577C (fr) 2014-01-07 2023-04-04 Bioatla, Llc Orthologues ciblant les proteines
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2938933A1 (fr) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anticorps anti-laminine4 specifiques contre lg4 -5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015136471A1 (fr) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anticorps anti-laminine 4 spécifiques de lg1-3
JP6728053B2 (ja) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド 抗ｍｃａｍ抗体及び関連する使用方法
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
EP3154585B1 (fr) 2014-06-11 2022-02-23 Kathy A. Green Utilisation d'antagonistes et d'agonistes vista pour supprimer ou améliorer l'immunité humorale
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
WO2015198240A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés permettant d'obtenir des protéines à action prolongée
EP3161001A2 (fr) 2014-06-25 2017-05-03 Novartis AG Anticorps spécifiques pour il-17a fusé à des étiquettes de peptide de liaison hyaluronan
WO2015198243A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés pour protéines à action longue
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3166688A4 (fr) 2014-07-08 2017-12-20 New York University Ligands de visualisation de tau et leurs utilisations dans le diagnostic et le traitement de tauopathies
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP3174901B1 (fr) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Constructions optimisées d'anticorps monocaténaires, bispécifiques, spécifiques d'espèces croisées
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP6692343B2 (ja) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
EP3194437B1 (fr) 2014-08-07 2021-01-20 Novartis AG Anticorps contre la protéine analogue à l'angiopoïétine 4 et leur utilisation
KR20240056627A (ko) 2014-08-07 2024-04-30 노파르티스 아게 안지오포이에틴-유사 4 항체 및 사용 방법
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CA2961210A1 (fr) 2014-09-15 2016-03-24 Abvitro, Inc. Sequencage a haut debit de banque de nucleotides
JP6716544B2 (ja) 2014-09-16 2020-07-01 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 競合的ｈｉｖ侵入阻害を媒介するｃｄ４に対するモノクローナル抗体によるｈｉｖ感染の処置および機能的治癒
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016059220A1 (fr) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents d'activation du tcr à utiliser dans le traitement de la lla-t
EP3207128B1 (fr) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Conjugués polymères zwittérioniques de butyrylcholinestérase
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
WO2016073894A1 (fr) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Agents thérapeutiques avec une rétention oculaire accrue
KR102636726B1 (ko) 2014-11-07 2024-02-13 에프. 호프만 라-로셰 엘티디 향상된 il-6 항체
MX2017006624A (es) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos contra cd73 y sus usos.
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
WO2016149088A1 (fr) 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Utilisation de lavages alcalins durant une chromatographie pour éliminer les impuretés
WO2016153978A1 (fr) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Utilisation de dextrane pour améliorer la purification de protéines par chromatographie d'affinité
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
KR102057767B1 (ko) 2015-04-17 2019-12-19 에프. 호프만-라 로슈 아게 응고 인자 및 다중특이적 항체의 조합 요법
SG10201909308XA (en) 2015-04-17 2019-11-28 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
EP3286214B1 (fr) 2015-04-24 2023-12-06 The Regents of the University of California Modulateurs de la liaison ror1-ror2
TW201713361A (zh) 2015-04-29 2017-04-16 Regeneron Pharma 進行性骨化性纖維發育不良之治療
CA2987410A1 (fr) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Anticorps anti-ox40 et leurs utilisations
WO2016193872A2 (fr) 2015-06-05 2016-12-08 Novartis Ag Anticorps ciblant la protéine morphogénétique osseuse 9 (bmp9) et méthodes associées
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
AU2016315892B2 (en) 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
NZ740067A (en) 2015-09-09 2021-07-30 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2017046776A2 (fr) 2015-09-16 2017-03-23 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'artérite à cellules géantes, la pseudo-polyarthrite rhizomélique ou l'artérite de takayasu
WO2017046774A2 (fr) 2015-09-16 2017-03-23 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'artérite à cellules géantes, la pseudo-polyarthrite rhizomélique ou l'artérite de takayasu
BR112018002432A2 (pt) 2015-09-18 2018-09-18 Chugai Pharmaceutical Co Ltd anticorpos de ligação à il-8 e usos dos mesmos
EP3933047A1 (fr) 2015-09-24 2022-01-05 AbVitro LLC Conjugés affinité-oligonucléotide et leurs utilisations
CN113774495A (zh) 2015-09-25 2021-12-10 阿布维特罗有限责任公司 用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
EP3378488A4 (fr) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Procédé pour renforcer la réponse immunitaire humorale
WO2017086367A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3383920B1 (fr) 2015-11-30 2024-01-10 The Regents of the University of California Administration de charge utile spécifique de tumeur et activation immunitaire au moyen d'un anticorps humain ciblant un antigène de surface de cellule tumorale très spécifique
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
UA126656C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Гмбх Біспецифічна конструкція антитіла до psma і cd3, яке залучають t-клітини
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MA43955B1 (fr) 2016-02-03 2022-02-28 Amgen Inc Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
WO2017149513A1 (fr) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anticorps anti-mcam et méthodes d'utilisation associées
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
KR102588359B1 (ko) 2016-03-04 2023-10-13 제이엔 바이오사이언시즈 엘엘씨 Tigit에 대한 항체
CN109476740A (zh) 2016-03-04 2019-03-15 百时美施贵宝公司 利用抗cd73抗体的联合治疗
WO2017153955A1 (fr) 2016-03-09 2017-09-14 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de maladies pulmonaires granulomateuses
WO2017153953A1 (fr) 2016-03-09 2017-09-14 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de maladies pulmonaires granulomateuses
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
WO2017157305A1 (fr) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Protéines de fusion à fab multispécifiques et leur utilisation
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
JP2019513749A (ja) 2016-04-07 2019-05-30 デューク ユニバーシティ 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
CN118108843A (zh) 2016-04-15 2024-05-31 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CH713803B1 (de) 2016-04-21 2023-08-15 4TEEN4 Pharmaceuticals GmbH Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer.
WO2017191560A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Anticorps reconnaissant tau
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
JP7012665B6 (ja) 2016-05-09 2023-12-14 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌ１ａ抗体およびその使用
WO2017208210A1 (fr) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anticorps anti-mcam et methodes d'utilisation associées
KR102410360B1 (ko) 2016-06-06 2022-06-17 시티 오브 호프 Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
WO2017214170A2 (fr) 2016-06-06 2017-12-14 City Of Hope Anticorps baff-r et utilisations de ceux-ci
WO2017216724A1 (fr) 2016-06-15 2017-12-21 Novartis Ag Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478715A2 (fr) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anticorps anti-transthyrétine
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007588A1 (fr) 2016-07-08 2018-01-11 Sphingotec Gmbh Adrénomédulline pour évaluation de la congestion chez un sujet atteint d'insuffisance cardiaque aiguë
CN116041504A (zh) 2016-07-12 2023-05-02 H.隆德贝克有限公司 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
CN118108847A (zh) 2016-08-07 2024-05-31 诺华股份有限公司 mRNA介导的免疫方法
EP3497112A1 (fr) 2016-08-12 2019-06-19 Bristol-Myers Squibb Company Procédés de purification de protéines
US11292839B2 (en) 2016-08-13 2022-04-05 Ubi Us Holdings, Llc Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients
WO2018044970A1 (fr) 2016-08-31 2018-03-08 University Of Rochester Anticorps monoclonaux humains dirigés contre l'enveloppe du rétrovirus endogène humain k (herv-k) et leurs utilisations
SG11201901961SA (en) 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
AU2017332495A1 (en) 2016-09-24 2019-04-11 Abvitro Llc Affinity-oligonucleotide conjugates and uses thereof
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
RS60886B1 (sr) * 2016-11-04 2020-11-30 Regeneron Pharma Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
US20200207846A1 (en) 2016-11-28 2020-07-02 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
EP3339324A1 (fr) 2016-12-22 2018-06-27 sphingotec GmbH Anticorps anti-adrénomedulline (adm) ou fragment d'anticorps anti-adm ou échafaudage anti-adm non-ig destiné à être utilisé dans l'intervention et la thérapie de congestion chez un patient ayantbesoin
CN110167962B (zh) 2016-12-16 2024-06-07 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CA3052911A1 (fr) 2017-02-08 2018-08-16 Novartis Ag Anticorps mimetiques du fgf21 et leurs utilisations
WO2018151821A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucléine et leurs utilisations
WO2018174274A1 (fr) 2017-03-24 2018-09-27 全薬工業株式会社 ANTICORPS BISPÉCIFIQUE ANTI-IgM/ANTIGÈNE DE SURFACE DE LYMPHOCYTE B
KR20240014600A (ko) 2017-03-24 2024-02-01 노바르티스 아게 심장질환 예방 및 치료 방법
EP3601362A4 (fr) 2017-03-30 2020-12-16 The Johns Hopkins University Système supramoléculaire de liaison protéique à haute affinité pour la purification de biomacromolécules
EP3603670A4 (fr) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University Composition médicinale utilisable pour prévenir et/ou traiter une anomalie du facteur ix de la coagulation sanguine, comprenant une molécule de liaison d'antigène multispécifique remplaçant la fonction du facteur viii de la coagulation sanguine
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018191548A2 (fr) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complément et leurs conjugués
JP7261739B2 (ja) 2017-04-27 2023-04-20 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
WO2018204546A2 (fr) 2017-05-02 2018-11-08 Prothena Biosciences Limited Anticorps reconnaissant la protéine tau
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
AU2018261951A1 (en) 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
AU2018273999A1 (en) 2017-05-26 2019-12-05 Abvitro Llc High-throughput polynucleotide library sequencing and transcriptome analysis
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
US20200199541A1 (en) 2017-06-16 2020-06-25 Imba - Institut Für Molekulare Biotechnologie Gmbh Blood vessel organoid, methods of producing and using said organoids
JP2020525421A (ja) 2017-06-28 2020-08-27 ノバルティス アーゲー 尿失禁を予防及び治療するための方法
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11745165B2 (en) 2017-08-18 2023-09-05 The Johns Hopkins University Supramolecular filamentous assemblies for protein purification
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
EP4159229A1 (fr) 2017-09-25 2023-04-05 AdrenoMed AG Liant anti-adrénomédulline (adm) destiné à être utilisé dans la thérapie ou la prévention de symptômes de maladie
BR112020005682A2 (pt) 2017-10-18 2020-10-20 Adrenomed Ag monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11530276B2 (en) 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
SG11202004627WA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand-binding activity
US20200377958A1 (en) 2017-12-01 2020-12-03 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
JP7344206B2 (ja) 2017-12-11 2023-09-13 アムジェン インコーポレイテッド 二重特異性抗体製品のための連続製造プロセス
EP3498293A1 (fr) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Traitement de maladies monogéniques avec un anticorps anti-cd45rc
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
WO2019140229A1 (fr) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Anticorps dirigés contre tim3 et leurs utilisations
EP3737699A1 (fr) 2018-01-12 2020-11-18 Amgen Inc. Anticorps pac1 et leurs utilisations
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
BR112020014940A2 (pt) 2018-02-08 2020-12-08 Sphingotec Gmbh Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência
WO2019183551A1 (fr) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Anticorps contre mica et/ou micb et leurs utilisations
KR20200136464A (ko) 2018-03-29 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 단량체성 모노클로날 항체를 정제하는 방법
EP3569614A1 (fr) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Composés et procédés pour l'immobilisation des inhibiteurs de myostatine sur la matrice extracellulaire par la transglutaminase
CN112512480A (zh) 2018-05-21 2021-03-16 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3586865A1 (fr) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Liants d'anaphylatoxine de complément et leur utilisation dans le traitement d'un sujet présentant une plaie oculaire et/ou une fibrose
CA3106833A1 (fr) 2018-07-20 2020-01-23 Aicuris Gmbh & Co. Kg Procedes de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucleaire du virus de l'herpes
TW202021616A (zh) 2018-07-30 2020-06-16 美商安進公司 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
EP3829633A1 (fr) 2018-08-03 2021-06-09 Amgen Research (Munich) GmbH Constructions d'anticorps pour cldn18.2 et cd3
WO2020041360A1 (fr) 2018-08-21 2020-02-27 Quidel Corporation Anticorps dbpa et leurs utilisations
CA3109732A1 (fr) 2018-08-27 2020-03-05 Affimed Gmbh Cellules nk cryoconservees prechargees avec une construction d'anticorps
AU2019342017A1 (en) 2018-09-18 2021-05-13 Merrimack Pharmaceuticals, Inc. Anti-TNFR2 antibodies and uses thereof
WO2020068653A1 (fr) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. ANTICORPS MULTISPÉCIFIQUES CIBLANT HPTP- β (VE-PTP) ET VEGF
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
EP3886869A4 (fr) 2018-11-28 2022-07-06 Forty Seven, Inc. Csph génétiquement modifiées résistantes au traitement ablatif
CN113557031A (zh) 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
CN113329770A (zh) 2019-01-24 2021-08-31 中外制药株式会社 新型癌抗原及所述抗原的抗体
WO2020175689A1 (fr) 2019-02-28 2020-09-03 学校法人順天堂 Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
CA3131953A1 (fr) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anticorps anti-tnfr2 et leurs utilisations
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
EP3948262A1 (fr) 2019-03-29 2022-02-09 Bristol-Myers Squibb Company Procédés de mesure de l'hydrophobicité de résines chromatographiques
JPWO2020209318A1 (fr) 2019-04-10 2020-10-15
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
JOP20210326A1 (ar) 2019-06-12 2023-01-30 Novartis Ag أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
EP3983520A1 (fr) 2019-06-13 2022-04-20 Amgen, Inc Commande de perfusion contenant de la biomasse automatisée dans la fabrication de produits biologiques
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
US20220307065A1 (en) 2019-08-30 2022-09-29 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
WO2021053559A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4058485A1 (fr) 2019-11-13 2022-09-21 Amgen Inc. Procédé de réduction de la formation d'agrégats dans le traitement en aval de molécules de liaison à l'antigène bispécifiques
US20210188971A1 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
WO2021127528A1 (fr) 2019-12-20 2021-06-24 Amgen Inc. Constructions d'anticorps multispécifique agoniste de cd40 ciblé par la mésothéline permettant le traitement de tumeurs solides
EP4081554A1 (fr) 2019-12-27 2022-11-02 Affimed GmbH Procédé de production de construction d'anticorps bispécifique fcyriii x cd30
CN115243763A (zh) 2020-01-08 2022-10-25 里珍纳龙药品有限公司 治疗进行性骨化性纤维发育不良
EP4093771A1 (fr) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
EP3871689A1 (fr) 2020-02-26 2021-09-01 sphingotec GmbH Anticorps anti-adm se liant à l'extrémité n-terminale libre pour accélérer la transition de l'adm-gly vers la bio-adm chez les patients dont le rapport adm-gly/bio-adm est supérieur à un seuil et combinaison avec la vitamine c
KR20220145897A (ko) 2020-02-27 2022-10-31 아드레노메드 아게 쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
KR20220145898A (ko) 2020-02-27 2022-10-31 아드레노메드 아게 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제
CN115244401A (zh) 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
AU2021238592A1 (en) 2020-03-16 2022-11-03 Sphingotec Gmbh Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against Adrenomedullin
EP3922993A1 (fr) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 chez des patients infectés par le coronavirus
BR112022017277A2 (pt) 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH Dpp3 em pacientes infectados com coronavírus
CA3175275A1 (fr) 2020-03-19 2021-09-23 Amgen Inc. Anticorps contre la mucine 17 et leurs utilisations
CN115335082A (zh) 2020-03-27 2022-11-11 光爱科技公司 用于杀死肿瘤细胞的医药品
CN115379858A (zh) 2020-04-06 2022-11-22 光爱科技公司 用于杀死肿瘤细胞的医药品
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2021220218A1 (fr) 2020-05-01 2021-11-04 Novartis Ag Variants d'immunoglobuline
JP2023523794A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 人工操作免疫グロブリン
EP3909601A1 (fr) 2020-05-11 2021-11-17 LeukoCom GmbH Nouvel anticorps se liant spécifiquement au ceacam 1/3/5 humain et son utilisation
WO2021231732A1 (fr) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Anticorps anti-garp
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CN115667515A (zh) 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit
US20230242554A1 (en) 2020-06-24 2023-08-03 The University Of Tokyo Photosensitizing dye
CA3186914A1 (fr) 2020-07-28 2022-02-03 Masakazu Fukuda Preparation de seringue pre-remplie dotee d'une aiguille, pourvue d'un protecteur d'aiguille et comprenant un nouvel anticorps modifie
EP4197545A1 (fr) 2020-07-31 2023-06-21 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique comprenant des cellules exprimant un récepteur chimérique
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
IL300764A (en) 2020-08-27 2023-04-01 Juntendo Educational Found Antibody and composition of calr-cd3 mutant anti-clotting drugs
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
WO2022096704A1 (fr) 2020-11-06 2022-05-12 Amgen Inc. Domaine de liaison à l'antigène à taux de coupure réduit
AU2021374839A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
CR20230235A (es) 2020-11-06 2023-10-05 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
JP2023547661A (ja) 2020-11-06 2023-11-13 アムジエン・インコーポレーテツド Ｃｄ３に結合するポリペプチド構築物
EP4023218A1 (fr) 2020-12-02 2022-07-06 S-Form Pharma Thérapie combinée pour les patients souffrant d'une dyspnée aiguë et/ou persistante
EP4259661A1 (fr) 2020-12-14 2023-10-18 Novartis AG Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
AU2022232856A1 (en) 2021-03-12 2023-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
WO2022212831A1 (fr) 2021-04-02 2022-10-06 Amgen Inc. Constructions de liaison à mageb2
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4376958A1 (fr) 2021-07-30 2024-06-05 Affimed GmbH Corps duplex
EP4144898A1 (fr) 2021-09-07 2023-03-08 New/era/mabs GmbH Procédé de sélection ou de dépistage des anticorps à partir d'une bibliothèque d'anticorps
WO2023048231A1 (fr) 2021-09-24 2023-03-30 株式会社PhotoQ3 Médicament destiné à tuer des cellules tumorales
WO2023057871A1 (fr) 2021-10-04 2023-04-13 Novartis Ag Stabilisants tensioactifs
JPWO2023058723A1 (fr) 2021-10-08 2023-04-13
CA3233696A1 (fr) 2021-11-03 2023-05-11 Joachim Koch Liants de cd16a bispecifiques
CA3237018A1 (fr) 2021-11-03 2023-05-11 Joachim Koch Liants de cd16a bispecifiques
WO2023175035A1 (fr) 2022-03-15 2023-09-21 Adrenomed Ag Formulation aqueuse stable d'un anticorps anti-adrénomédulline (adm) ou d'un fragment d'anticorps anti-adm
WO2023209568A1 (fr) 2022-04-26 2023-11-02 Novartis Ag Anticorps multispécifiques ciblant il-13 et il-18
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2024023369A1 (fr) 2022-07-29 2024-02-01 Adrenomed Ag Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm destiné à être utilisé en thérapie ou prévention du choc
WO2024023368A1 (fr) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prédiction d'augmentation de dpp3 chez un patient souffrant d'un choc septique
WO2024059675A2 (fr) 2022-09-14 2024-03-21 Amgen Inc. Composition de stabilisation de molécule bispécifique
EP4345109A1 (fr) 2022-09-30 2024-04-03 AdrenoMed AG Liant anti-adrénomédulline (adm) destiné à être utilisé dans la thérapie de patients pédiatriques atteints de cardiopathie congénitale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (fr) * 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
SG48759A1 (en) * 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물

Also Published As

Publication number Publication date
EP0746609A4 (fr) 1997-12-17
WO1993012227A1 (fr) 1993-06-24
EP0746609A1 (fr) 1996-12-11
JP2004008218A (ja) 2004-01-15
CA2124967A1 (fr) 1993-06-24
AU3328493A (en) 1993-07-19
JPH07503132A (ja) 1995-04-06

Similar Documents

Publication Publication Date Title
CA2124967C (fr) Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en) Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) Transgenic non-human animals for producing heterologous antibodies
US5569825A (en) Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2161351C (fr) Animaux transgeniques, pouvant produire des anticorps heterologues
US5633425A (en) Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) Transgenic non-human animals for producing heterologous antibodies
CA2232813C (fr) Animaux non humains transgeniques pouvant produire des anticorps heterologues
AU747370B2 (en) Transgenic non-human animals capable of producing heterologous antibo dies
US5874299A (en) Transgenic non-human animals capable of producing heterologous antibodies
US8231877B2 (en) Heterologous antibodies which bind human CD4
US8158419B2 (en) Transgenic non-human animals for producing chimeric antibodies
WO1998024884A9 (fr) Animaux transgeniques non humains capables de produire des anticorps heterologues
JPH08140528A (ja) 異種抗体を産生することができるトランスジェニック非ヒト動物
EP1288229A2 (fr) Animaux transgéniques non humains, capables de fabriquer des anticorps hétérologues
AU720612B2 (en) Transgenic non-human animals capable of producing heterologous antibodies
AU2003204055B2 (en) Transgenic non-human animals capable of producing heterologous antibodies

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20121217